Epigenome and DNA methylation in oral squamous cell carcinoma

Methods in Molecular Biology

Volumn 863, Issue , 2012, Pages 207-219

  García, Mario Pérez Sayáns ^a   García García, Abel ^a  

^a Oral Surgery and Implantology Unit   (Spain)

Author keywords

Deacetylation; Epigenetics; Histones; Hypermethylation; Oral squamous cell carcinoma

Indexed keywords

CYTOSINE; HISTONE;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; CPG ISLAND; DNA METHYLATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; MOUTH TUMOR; PHOSPHORYLATION; PHYSIOLOGY; SQUAMOUS CELL CARCINOMA; UBIQUITINATION;

CARCINOMA, SQUAMOUS CELL; CPG ISLANDS; CYTOSINE; DNA METHYLATION; EPIGENESIS, GENETIC; HISTONES; MOLECULAR STRUCTURE; MOUTH NEOPLASMS; PHOSPHORYLATION; UBIQUITINATION;

MAMMALIA;

EID: 84859994239     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-612-8_12     Document Type: Article

References (104)

1. S. Gao, J. Worm, P. Guldberg, H. Eiberg, A. Krogdahl, C. J. Liu, J. Reibel, and E. Dabelsteen, (2004) Genetic and epigenetic alterations of the blood group ABO gene in oral squamous cell carcinoma. Int J Cancer 109, 230-237. (Pubitemid 38240925)
2. M. Perez-Sayans, J. M. Somoza-Martin, F. Barros-Angueira, M. D. Reboiras-Lopez, J. M. Gandara Rey, and A. Garcia-Garcia (2009) Genetic and molecular alterations associated with oral squamous cell cancer (review). Oncol Rep 22, 1277-1282.
3. A. Bird, (2002) DNA methylation patterns and epigenetic memory. Genes. Dev. 16, 6-21. (Pubitemid 34049633)
4. T. Vaissiere, C. Sawan, and Z. Herceg (2008) Epigenetic interplay between histone modifi -cations and DNA methylation in gene silencing. Mutat Res 659, 40-48.
5. J. Murakami, J. Asaumi, Y. Maki , et al (2004) Infl uence of CpG island methylation status in O6-methylguanine-DNA methyltransferase expression of oral cancer cell lines. Oncol Rep 12, 339-345.
6. C. J. Piyathilake, W. C. Bell, J. Jones, O. L. Henao, D. C. Heimburger, A. Niveleau, and W. E. Grizzle (2005) Patterns of global DNA and histone methylation appear to be similar in normal, dysplastic and neoplastic oral epithelium of humans. Dis Markers 21, 147-151. (Pubitemid 41566733)
7. F. Larsen, G. Gundersen, R. Lopez, and H. Prydz (1992) CpG islands as gene markers in the human genome. Genomics 13, 1095-1107.
8. P. K. Ha and J. A. Califano (2006) Promoter methylation and inactivation of tumoursuppressor genes in oral squamous-cell carcinoma. Lancet Oncol 7, 77-82. (Pubitemid 43025396)
9. K. Gronbaek, C. Hother, and P. A. Jones (2007) Epigenetic changes in cancer. APMIS 115, 1039-1059. (Pubitemid 350179474)
10. A. T. Hark, C. J. Schoenherr, D. J. Katz, R. S. Ingram, J. M. Levorse, and S. M. Tilghman (2000) CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature 405, 486-489. (Pubitemid 30367428)
11. J. Murakami, J. Asaumi, N. Kawai , et al (2005) Effects of histone deacetylase inhibitor FR901228 on the expression level of telomerase reverse transcriptase in oral cancer, Cancer Chemother Pharmacol 56, 22-28. (Pubitemid 41201752)
12. A. P. Bird and A. P. Wolffe (1999) Methylationinduced repression-belts, braces, and chromatin. Cell 99, 451-454.
13. A. P. Feinberg (2001) Cancer epigenetics takes center stage. Proc. Natl. Acad. Sci. USA 98, 392-394. (Pubitemid 32105049)
14. M. Mancuso, D. S. Matassa, M. Conte, G. Colella, G. Rana, L. Fucci, and M. Piscopo (2009) H3K4 histone methylation in oral squamous cell carcinoma. Acta Biochim Pol 56, 405-410.
15. E. A. Vucic, C. J. Brown, and W. L. Lam (2008) Epigenetics of cancer progression. Pharmacogenomics 9, 215-234. (Pubitemid 351575091)
16. R. L. Momparler and V. Bovenzi (2000) DNA methylation and cancer. J Cell Physiol 183, 145-154. (Pubitemid 30185933)
17. M. Cruz-Correa, H. Cui, F. M. Giardiello , et al (2004) Loss of imprinting of insulin growth factor II gene: A potential heritable biomarker for colon neoplasia predisposition. Gastroenterology 126, 964-970. (Pubitemid 38451167)
18. X. Wu, H. Zhao, R. Suk, and D. C. Christiani (2004) Genetic susceptibility to tobaccorelated cancer. Oncogene 23, 6500-6523.
19. D. Hanahan and R. A. Weinberg (2000) The hallmarks of cancer. Cell 100, 57-70. (Pubitemid 30046295)
20. S. Choi and J. N. Myers (2008) Molecular pathogenesis of oral squamous cell carcinoma: Implications for therapy. J Dent Res 87, 14-32.
21. A. K. El-Naggar, S. Lai, G. Clayman, J. K. Lee, M. A. Luna, H. Goepfert, and J. G. (1997) Batsakis, Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma. Am. J. Pathol. 151, 1767-1774. (Pubitemid 27527939)
22. R. Sailasree, A. Abhilash, K. M. Sathyan, K. R. Nalinakumari, S. Thomas, and S. Kannan. (2008) Differential roles of p16INK4A and p14ARF genes in prognosis of oral carcinoma. Cancer Epidemiol. Biomarkers Prev. 17, 414-420. (Pubitemid 351272795)
23. R. J. Shaw, T. Liloglou, S. N. Rogers, J. S. Brown, E. D. Vaughan, D. Lowe, J. K. Field, and J. M. Risk (2006) Promoter methylation of P16, RARbeta, E-cadherin, cyclin A1 and cytoglobin in oral cancer: Quantitative evaluation using pyrosequencing, Br J Cancer 94. 561-568. (Pubitemid 43289761)
24. C. Motsch, A. Giers, C. Boltze, M. Evert, B. Freigang, A. Roessner, and R. Schneider-Stock (2004) Biallelic inactivation of the p16-gen in a metachronous triple carcinoma in the oropharyngeal region. Laryngorhinootologie 83, 55-60. (Pubitemid 38196788)
25. S. Shintani, Y. Nakahara, M. Mihara, Y. Ueyama, and T. Matsumura (2001) Inactivation of the p14(ARF), p15(INK4B) and p16(INK4A) genes is a frequent event in human oral squamous cell carcinomas. Oral Oncol 37, 498-504. (Pubitemid 32588775)
26. K. Ogi, M. Toyota, M. Ohe-Toyota, N. Tanaka, M. Noguchi, T. Sonoda, G. Kohama, and T. Tokino (2002) Aberrant methylation of multiple genes and clinicopathological features in oral squamous cell carcinoma. Clin. Cancer Res. 8, 3164-3171. (Pubitemid 35155026)
27. S. Maruya, J. P. Issa, R. S. Weber, D. I. Rosenthal, J. C. Haviland, R. Lotan, and A. K. El-Naggar (2004) Differential methylation status of tumor-Associated genes in head and neck squamous carcinoma: Incidence and potential implications. Clin. Cancer Res. 10, 3825-3830. (Pubitemid 38697618)
28. M. Gasco, A. K. Bell, V. Heath , et al (2002) Epigenetic inactivation of 14-3-3 sigma in oral carcinoma: Association with p16(INK4a) silencing and human papillomavirus negativity. Cancer Res. 62, 2072-2076. (Pubitemid 34408454)
29. T. Daa, K. Kashima, Y. Kondo, N. Yada, M. Suzuki, and S. Yokoyama (2008) Aberrant methylation in promoter regions of cyclindependent kinase inhibitor genes in adenoid cystic carcinoma of the salivary gland. APMIS 116, 21-26. (Pubitemid 351191100)
30. M. J. Huang, K. T. Yeh, H. C. Shih, Y. F. Wang, T. H. Lin, J. Y. Chang, M. C. Shih, and J. G. Chang (2002) The correlation between CpG methylation and protein expression of P16 in oral squamous cell carcinomas. Int J. Mol. Med. 10, 551-554.
31. S. Ohta, H. Uemura, Y. Matsui , et al (2009) Alterations of p16 and p14ARF genes and their 9p21 locus in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 107, 81-91.
32. M. A. Gonzalez-Moles, J. A. Gil-Montoya, I. Ruiz-Avila, F. Esteban, M. Delgado-Rodriguez, and A. Bascones-Martinez (2007) Prognostic signifi cance of p21WAF1/CIP1, p16INK4a and CD44s in tongue cancer. Oncol Rep 18, 389-396.
33. U. K. Bhawal, K. Tsukinoki, T. Sasahira, F. Sato, Y. Mori, N. Muto, M. Sugiyama, and H. Kuniyasu (2007) Methylation and intratumoural heterogeneity of 14-3-3 sigma in oral cancer. Oncol Rep 18, 817-824.
34. S. M. Dong, D. I. Sun, N. E. Benoit, I. Kuzmin, M. I. Lerman, and D. Sidransky, (2003). Epigenetic inactivation of RASSF1A in head and neck cancer, Clin. Cancer Res. 9, 3635-3640. (Pubitemid 37169228)
35. K. H. Huang, S. F. Huang, I. H. Chen, C. T. Liao, H. M. Wang, and L. L. Hsieh (2009) Methylation of RASSF1A, RASSF2A, and HIN-1 is associated with poor outcome after radiotherapy, but not surgery, in oral squamous cell carcinoma. Clin. Cancer Res. 15, 4174-4180.
36. T. N. Tran, Y. Liu, M. Takagi, A. Yamaguchi, and H. Fujii (2005) Frequent promoter hypermethylation of RASSF1A and p16INK4a and infrequent allelic loss other than 9p21 in betel-Associated oral carcinoma in a vietnamese non-smoking/non-drinking female population. J Oral Pathol Med 34, 150-156. (Pubitemid 40293223)
37. T. Imai, M. Toyota, H. Suzuki , et al (2008) Epigenetic inactivation of RASSF2 in oral squamous cell carcinoma. Cancer Sci 99, 958-966. (Pubitemid 351997598)
38. M. Nishimine, M. Nakamura, M. Kishi, M. Okamoto, K. Shimada, E. Ishida, T. Kirita, and N. Konishi (2003) Alterations of p14ARF and p16INK4a genes in salivary gland carcinomas. Oncol Rep 10, 555-560.
39. C. A. Righini, F. de Fraipont, E. Reyt, and M. C. Favrot (2007) Aberrant methylation of tumor suppressor genes in head and neck squamous cell carcinoma: Is it clinically relevant? Bull Cancer 94, 191-197. (Pubitemid 46456113)
40. V. Kulkarni and D. Saranath (2004) Concurrent hypermethylation of multiple regulatory genes in chewing tobacco associated oral squamous cell carcinomas and adjacent normal tissues. Oral Oncol 40, 145-153. (Pubitemid 38030357)
41. K. T. Yeh, J. G. Chang, T. H. Lin, Y. F. Wang, N. Tien, J. Y. Chang, J. C. Chen, and M. C. Shih (2003) Epigenetic changes of tumor suppressor genes, P15, P16, VHL and P53 in oral cancer. Oncol Rep 10, 659-663.
42. S. Nakayama, A. Sasaki, H. Mese, R. E. Alcalde, T. Tsuji, and T. Matsumura (2001) The E-cadherin gene is silenced by CpG methylation in human oral squamous cell carcinomas. Int J Cancer 93, 667-673. (Pubitemid 32695114)
43. Y. Saito, H. Takazawa, K. Uzawa, H. Tanzawa, and K. Sato (1998) Reduced expression of E-cadherin in oral squamous cell carcinoma: Relationship with DNA methylation of 5 ¢CpG island. Int J Oncol 12, 293-298.
44. H. W. Chang, V. Chow, K. Y. Lam, W. I. Wei, and A. Yuen (2002) Loss of E-cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic signifi cance. Cancer 94, 386-392. (Pubitemid 34081367)
45. G. Maeda, T. Chiba, T. Aoba, and K. Imai (2007) Epigenetic inactivation of E-cadherin by promoter hypermethylation in oral carcinoma cells. Odontology 95, 24-29.
46. R. V. de Moraes, D. T. Oliveira, G. Landman, F. de Carvalho, O. Caballero, S. Nonogaki, I. Nishimoto, and L. P. Kowalski (2008) E-cadherin abnormalities resulting from CPG methylation promoter in metastatic and nonmetastatic oral cancer. Head Neck 30, 85-92. (Pubitemid 351158325)
47. S. Gao, E. P. Bennett, J. Reibel, X. Chen, M. E. Christensen, A. Krogdahl, and E. Dabelsteen (2004) Histo-blood group ABO antigen in oral potentially malignant lesions and squamous cell carcinoma-genotypic and phenotypic characterization. APMIS 112, 11-20. (Pubitemid 38297161)
48. G. Maeda, T. Chiba, S. Kawashiri, T. Satoh, and K. Imai (2007) Epigenetic inactivation of IkappaB kinase-Alpha in oral carcinomas and tumor progression. Clin. Cancer Res. 13, 5041-5047. (Pubitemid 47505179)
49. S. Ogane, T. Onda, N. Takano, T. Yajima, T. Uchiyama, and T. Shibahara (2009) Spleen tyrosine kinase as a novel candidate tumor suppressor gene for human oral squamous cell carcinoma. Int J Cancer 124, 2651-2657.
50. K. Liu, H. Huang, P. Mukunyadzi, J. Y. Suen, E. Hanna, and C. Y. Fan (2002) Promoter hypermethylation: An important epigenetic mechanism for hMLH1 gene inactivation in head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 126, 548-553. (Pubitemid 41123543)
51. M. Viswanathan, N. Tsuchida, and G. Shanmugam (2003) Promoter hypermethylation profile of tumor-Associated genes p16, p15, hMLH1, MGMT and E-cadherin in oral squamous cell carcinoma. Int J Cancer 105, 41-46. (Pubitemid 36418483)
52. S. L. Rosas, W. Koch, M. G. Da Costa Carvalho, L. Wu, J. Califano, W. Westra, J. Jen, and D. Sidransky (2001) Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-Associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res. 61, 939-942. (Pubitemid 32174408)
53. C. Zuo, L. Ai, P. Ratliff, J. Y. Suen, E. Hanna, T. P. Brent, and C. Y. Fan (2004) O6-methylguanine-DNA methyltransferase gene: Epigenetic silencing and prognostic value in head and neck squamous cell carcinoma. Cancer Epidemiol. Biomarkers Prev. 13, 967-975. (Pubitemid 38756707)
54. F. Aniello, G. Colella, G. Muscariello, A. Lanza, D. Ferrara, M. Branno, and S. Minucci (2006) Expression of four histone lysinemethyltransferases in parotid gland tumors. Anticancer Res 26, 2063-2067. (Pubitemid 43989470)
55. S. Mitra, S. Banerjee, C. Misra, R. K. Singh, A. Roy, A. Sengupta, C. K. Panda, and S. Roychoudhury (2007) Interplay between human papilloma virus infection and p53 gene alterations in head and neck squamous cell carcinoma of an Indian patient population. J. Clin. Pathol 60, 1040-1047. (Pubitemid 47441939)
56. L. Ai, Q. N. Vo, C. Zuo, L. Li, W. Ling, J. Y. Suen, E. Hanna, K. D. Brown, and C. Y. Fan (2004) Ataxia-Telangiectasia-mutated (ATM) gene in head and neck squamous cell carcinoma: Promoter hypermethylation with clinical correlation in 100 cases. Cancer Epidemiol. Biomarkers Prev. 13, 150-156. (Pubitemid 38116634)
57. M. Esteller, P. G. Corn, S. B. Baylin, and J. G. Herman (2001) A gene hypermethylation profile of human cancer. Cancer Res. 61, 3225-3229. (Pubitemid 32695003)
58. M. Sanchez-Cespedes, M. Esteller, L. Wu, H. Nawroz-Danish, G. H. Yoo, W. M. Koch, J. Jen, J. G. Herman, and D. Sidransky (2000) Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res. 60, 892-895. (Pubitemid 30129522)
59. J. B. Engel, A. V. Schally, G. Halmos, B. Baker, A. Nagy, and G. Keller (2005) Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1. Cancer 104, 1312-1321. (Pubitemid 41278968)
60. M. Koshiyama, H. Fujii, M. Kinezaki, Y. Morita, H. Nanno, and M. Yoshida (2001) Immunohistochemical expression of topoisomerase IIalpha (topo IIalpha) and multidrug resistance-Associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas. Anticancer Res 21, 2925-2932. (Pubitemid 33051153)
61. M. Perez-Sayans, J. M. Somoza-Martin, F. Barros-Angueira, P. G. Diz, J. M. Rey, and A. Garcia-Garcia (2010) Multidrug resistance in oral squamous cell carcinoma: The role of vacuolar ATPases. Cancer Lett 295, 135-43
62. R. Shaw (2006) The epigenetics of oral cancer. Int J Oral Maxillofac Surg 35, 101-108. (Pubitemid 43079020)
63. M. Toyota, C. Ho, N. Ahuja, K. W. Jair, Q. Li, M. Ohe-Toyota, S. B. Baylin, and J. P. Issa (1999) Identifi cation of differentially methylated sequences in colorectal cancer by methylated CpG island amplifi cation. Cancer Res. 59, 2307-2312. (Pubitemid 29242273)
64. K. Saito, K. Uzawa, Y. Endo, Y. Kato, D. Nakashima, K. Ogawara, M. Shiba, H. Bukawa, H. Yokoe, and H. Tanzawa (2006) Plasma membrane Ca2+ ATPase isoform 1 down-regulated in human oral cancer. Oncol Rep 15, 49-55.
65. T. Onda, K. Uzawa, Y. Endo, H. Bukawa, H. Yokoe, T. Shibahara, and H. Tanzawa (2006) Ubiquitous mitochondrial creatine kinase downregulated in oral squamous cell carcinoma. Br J Cancer 94, 698-709. (Pubitemid 43361902)
66. T. Nakagawa, A. Pimkhaokham, E. Suzuki, K. Omura, J. Inazawa, and I. Imoto (2006) Genetic or epigenetic silencing of low density lipoprotein receptor-related protein 1B expression in oral squamous cell carcinoma. Cancer Sci 97, 1070-1074. (Pubitemid 44322556)
67. E. Suzuki, I. Imoto, A. Pimkhaokham, T. Nakagawa, N. Kamata, K. I. Kozaki, T. Amagasa, and J. Inazawa (2007) PRTFDC1, a possible tumor-suppressor gene, is frequently silenced in oral squamous-cell carcinomas by aberrant promoter hypermethylation. Oncogene 26, 7921-7932. (Pubitemid 350261784)
68. E. Nakamura, K. Kozaki, H. Tsuda , et al (2008) Frequent silencing of a putative tumor suppressor gene melatonin receptor 1 A (MTNR1A) in oral squamous-cell carcinoma. Cancer Sci 99, 1390-1400. (Pubitemid 351761729)
69. Y. Kurasawa, M. Shiiba, M. Nakamura, K. Fushimi, T. Ishigami, H. Bukawa, H. Yokoe, K. Uzawa, and H. Tanzawa (2008) PTEN expression and methylation status in oral squamous cell carcinoma. Oncol Rep 19, 1429-1434.
70. Y. Sogabe, H. Suzuki, M. Toyota, K. Ogi, T. Imai, M. Nojima, Y. Sasaki, H. Hiratsuka, and T. Tokino (2008) Epigenetic inactivation of SFRP genes in oral squamous cell carcinoma. Int J Oncol 32, 1253-1261.
71. F. Gao, C. Huang, M. Lin, Z. Wang, J. Shen, H. Zhang, L. Jiang, and Q. Chen (2009) Frequent inactivation of RUNX3 by promoter hypermethylation and protein mislocalization in oral squamous cell carcinomas. J Cancer Res. Clin. Oncol. 135, 739-747.
72. A. Negishi, M. Masuda, M. Ono , et al (2009) Quantitative proteomics using formalinfi xed paraffi n-embedded tissues of oral squamous cell carcinoma. Cancer Sci 100, 1605-1611.
73. T. Chiba, G. Maeda, S. Kawashiri, K. Kato, and K. Imai (2009) Epigenetic loss of mucosaassociated lymphoid tissue 1 expression in patients with oral carcinomas. Cancer Res. 69, 7216-7223.
74. S. Gao, B. S. Nielsen, A. Krogdahl, J. A. Sorensen, J. Tagesen, S. Dabelsteen, E. Dabelsteen, and P. A. Andreasen (2010) Epigenetic alterations of the SERPINE1 gene in oral squamous cell carcinomas and normal oral mucosa. Genes Chromosomes Cancer 49, 526-538.
75. T. M. Richter, B. D. Tong, and S. B. Scholnick (2005) Epigenetic inactivation and aberrant transcription of CSMD1 in squamous cell carcinoma cell lines. Cancer Cell Int 5, 29.
76. S. A. Leon, G. E. Ehrlich, B. Shapiro, and V. A. Labbate (1977) Free DNA in the serum of rheumatoid arthritis patients. J Rheumatol 4, 139-143.
77. B. Shapiro, M. Chakrabarty, E. M. Cohn, and S. A. Leon (1983) Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer 51, 2116-2120. (Pubitemid 13092467)
78. A. Ziegler, U. Zangemeister-Wittke, and R. A. Stahel (2002) Circulating DNA: A new diagnostic gold mine? Cancer Treat Rev 28, 255-271. (Pubitemid 35439439)
79. M. Lopez, J. M. Aguirre, N. Cuevas, M. Anzola, J. Videgain, J. Aguirregaviria, and M. Martinez de Pancorbo (2003) Gene promoter hypermethylation in oral rinses of leukoplakia patients-A diagnostic and/or prognostic tool? Eur J Cancer 39, 2306-2309. (Pubitemid 37214854)
80. M. M. Coombes, K. L. Briggs, J. R. Bone, G. L. Clayman, A. K. El-Naggar, and S. Y. Dent (2003) Resetting the histone code at CDKN2A in HNSCC by inhibition of DNA methylation, Oncogene 22, 8902-8911. (Pubitemid 38021506)
81. M. Daskalakis, T. T. Nguyen, C. Nguyen, P. Guldberg, G. Kohler, P. Wijermans, P. A. Jones, and M. Lubbert (2002) Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2 ¢ -deoxycytidine (decitabine) treatment. Blood 100, 2957-2964.
82. J. Gilbert, S. D. Gore, J. G. Herman, and M. A. Carducci (2004) The clinical application of targeting cancer through histone acetylation and hypomethylation. Clin. Cancer Res. 10, 4589-4596. (Pubitemid 38955507)
83. J. L. Marshall, N. Rizvi, J. Kauh , et al (2002) A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol 2, 325-332. (Pubitemid 35265981)
84. V. Sandor, S. Bakke, R. W. Robey , et al (2002) Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res. 8, 718-728. (Pubitemid 34742100)
85. A. D. Donald, V. L. Clark, S. Patel , et al (2010) Design and synthesis of novel pyrimidine hydroxamic acid inhibitors of histone deacetylases. Bioorg Med Chem Lett 20, 6657-6660.
86. H. C. Yoon, E. Choi, J. E. Park , et al (2010) Property based optimization of delta-lactam HDAC inhibitors for metabolic stability. Bioorg Med Chem Lett 20, 6808-6811.
87. J. Kim, J. Guan, I. Chang, X. Chen, D. Han, and C. Y. Wang (2010) PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells. Mol. Cancer Ther 9, 1977-1984.
88. M. Nishimine, N. Konishi, K. Yamamoto, H. Nagai, M. Emi, T. Kirita, and M. Sugimura (2000) Epigenetic alterations in methylation in oral squamous cell carcinoma cell lines detected by two-dimensional gel electrophoresis. Int J Oncol 17, 743-747.
89. D. J. Smiraglia, L. T. Smith, J. C. Lang, L. J. Rush, Z. Dai, D. E. Schuller, and C. Plass (2003). Differential targets of CpG island hypermethylation in primary and metastatic head and neck squamous cell carcinoma (HNSCC). J Med Genet 40, 25-33. (Pubitemid 36115121)
90. S. Choudhuri, Y. Cui, and C. D. Klaassen (2010) Molecular targets of epigenetic regulation and effectors of environmental infl uences. Toxicol Appl Pharmacol 245, 378-393.
91. A. P. Feinberg (2008) Epigenetics at the epicenter of modern medicine. JAMA 299, 1345-1350. (Pubitemid 351439080)
92. M. F. Fraga, E. Ballestar, A. Villar-Garea , et al (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 37, 391-400.
93. T. Ryba, I. Hiratani, J. Lu, M. Itoh, M. Kulik, J. Zhang, T. C. Schulz, A. J. Robins, S. Dalton, and D. M. Gilbert (2010) Evolutionarily conserved replication timing profi les predict long-range chromatin interactions and distinguish closely related cell types. Genome Res 20, 761-770.
94. N. M. Boyd and P. C. Reade (1988) Differences between preneoplastic cells, neoplastic cells and their normal counterparts. J Oral Pathol 17, 257-265.
95. B. C. Richardson (2002) Role of DNA methylation in the regulation of cell function: Autoimmunity, aging and cancer. J Nutr 132, 2401S-2405S. (Pubitemid 34848115)
96. K. Gronbaek, M. Treppendahl, F. Asmar, and P. Guldberg (2008) Epigenetic changes in cancer as potential targets for prophylaxis and maintenance therapy. Basic. Clin. Pharmacol. Toxicol. 103, 389-396.
97. D. C. Dolinoy, D. Huang, and R. L. Jirtle (2007) Maternal nutrient supplementation counteracts bisphenol A-induced DNA hypomethylation in early development. Proc. Natl. Acad. Sci. USA 104, 13056-13061. (Pubitemid 351737592)
98. J. A. Yoder, C. P. Walsh, and T. H. Bestor (1997) Cytosine methylation and the ecology of intragenomic parasites. Trends Genet 13, 335-340. (Pubitemid 27309911)
99. S. P. Barros and S. Offenbacher (2009) Epigenetics: Connecting environment and genotype to phenotype and disease. J Dent Res 88, 400-408.
100. E. A. Miska (2005) How microRNAs control cell division, differentiation and death. Curr. Opin. Genet. Dev. 15, 563-568. (Pubitemid 41262414)
101. P. D. Zamore and B. Haley (2005) Ribognome: The big world of small RNAs, Science 309, 1519-1524. (Pubitemid 41266468)
102. K. T. Yeh, J. G. Chang, T. H. Lin, Y. F. Wang, J. Y. Chang, M. C. Shih, and C. C. Lin (2003) Correlation between protein expression and epigenetic and mutation changes of wnt pathway-related genes in oral cancer. Int J Oncol 23, 1001-1007.
103. W. S. Post, P. J. Goldschmidt-Clermont, C. C. Wilhide, A. W. Heldman, M. S. Sussman, P. Ouyang, E. E. Milliken, and J. P. Issa (1999) Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc Res 43, 985-991. (Pubitemid 29413198)
104. D. J. Barker, J. G. Eriksson, T. Forsen, and C. Osmond (2002) Fetal origins of adult disease: Strength of effects and biological basis. Int J Epidemiol 31, 1235-1239. (Pubitemid 36204489)